3D Tumor Model Feasibility Consultation

A focused consultation for academic, biotech, and pharma teams exploring whether a 3D bioprinting-enabled tumor model is appropriate for their research question.

NAMina Bio evaluates the biological model, sample type, therapeutic question, assay endpoint, and translational objective to design a feasible 3D model-development roadmap.

This service may include:

• Review of cell line, organoid, tumoroid, or patient-derived model suitability• Assessment of mono-culture, tumor–stroma, or tumor–immune model options• Recommended 3D architecture and matrix strategy• Suggested readouts, including viability, imaging, immunofluorescence, RNA/protein recovery, or omics integration• Preliminary project scope, timeline, and budget estimate• Go/no-go recommendations for model development or drug-response profiling

Best for: teams that want to explore 3D tumor modeling before committing to a full experimental program.

Research use only. This service does not include wet-lab execution, diagnostic testing, or clinical treatment recommendations.